Apart from the above agents, there are some early results of novel agents such as mTOR (mammalian target of rapamycin) inhibitors [33], monoclonal antibodies anti-CD30 [34], and anti-CD4 [35] that they may be active in T-cell lymphomas. This evidence concerns the gene MTOR and T-cell non-Hodgkin lymphoma.